Type II Diabetes Mellitus

Type II Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and relative insulin deficiency, leading to persistent hyperglycemia. In veterinary medicine, T2DM is most commonly recognized in cats, where it shares many pathophysiological features with human T2DM, including pancreatic beta-cell dysfunction and peripheral insulin resistance. Unlike Type I Diabetes Mellitus (T1DM), which involves absolute insulin deficiency due to immune-mediated beta-cell destruction, T2DM is often associated with obesity, physical inactivity, and genetic predisposition. The disease progresses through stages: early insulin resistance with compensatory hyperinsulinemia, followed by progressive beta-cell failure and eventual overt hyperglycemia. In cats, T2DM can sometimes be induced to remission with early aggressive treatment and weight management, whereas in dogs, diabetes mellitus is almost exclusively T1DM or insulin-dependent, with T2DM being extremely rare. The systemic consequences of chronic hyperglycemia include glucotoxicity, lipotoxicity, oxidative stress, and microvascular damage, leading to complications such as diabetic ketoacidosis (DKA), cataracts (in dogs), peripheral neuropathy, and increased susceptibility to infections.

The exact etiology of T2DM is multifactorial, involving genetic, environmental, and metabolic factors. In cats, the primary underlying cause is insulin resistance, often triggered by obesity, which leads to decreased insulin receptor sensitivity and impaired glucose uptake in peripheral tissues. Chronic overnutrition and a sedentary lifestyle contribute to visceral fat accumulation, which secretes pro-inflammatory adipokines (e.g., tumor necrosis factor-alpha, interleukin-6) that interfere with insulin signaling. Genetic predisposition plays a role, with certain cat breeds (e.g., Burmese) showing a higher incidence. Other etiological factors include chronic pancreatitis, which can damage beta-cells, and administration of diabetogenic drugs such as glucocorticoids or progestogens. In dogs, T2DM is extremely rare; most canine diabetes is immune-mediated T1DM, but secondary diabetes can occur due to pancreatitis, hyperadrenocorticism, or exogenous glucocorticoid therapy. In both species, amyloid deposition in the pancreatic islets (islet amyloid polypeptide) is a characteristic finding in T2DM and contributes to beta-cell destruction. Additionally, chronic hyperglycemia itself exacerbates insulin resistance and beta-cell dysfunction, creating a vicious cycle.

T2DM is predominantly a disease of middle-aged to older cats, with a median age of onset around 10-13 years. There is no strong sex predilection, but neutered male cats may be at slightly higher risk. Certain breeds, such as Burmese cats, have a higher genetic predisposition. Obesity is a major risk factor, with studies showing that overweight cats have a 2-4 times higher risk of developing diabetes. The incidence in cats has increased in parallel with rising obesity rates in the pet population. In dogs, T2DM is exceedingly rare; the vast majority of canine diabetes is insulin-dependent (T1DM), with an estimated prevalence of 0.2-1% in the general dog population. Breeds such as Samoyeds, Miniature Schnauzers, and Poodles are predisposed to diabetes, but this is typically T1DM. Geographic variation is minimal, but indoor confinement and high-carbohydrate diets are associated with higher risk in cats. Seasonality is not significant, but stress (e.g., boarding, illness) can precipitate clinical signs in predisposed individuals.

The pathophysiology of T2DM involves a complex interplay between insulin resistance and beta-cell dysfunction. Initially, insulin resistance in peripheral tissues (muscle, adipose, liver) leads to reduced glucose uptake and increased hepatic glucose production. To compensate, pancreatic beta-cells increase insulin secretion, resulting in hyperinsulinemia. Over time, chronic hyperglycemia and hyperlipidemia exert toxic effects on beta-cells (glucotoxicity and lipotoxicity), leading to progressive beta-cell failure and decreased insulin secretion. Additionally, islet amyloid polypeptide (amylin) is co-secreted with insulin and can aggregate to form amyloid deposits in the islets, further damaging beta-cells. In cats, the pancreatic islets often show amyloid deposition, which is a hallmark of T2DM. The resulting insulin deficiency leads to decreased glucose utilization, increased gluconeogenesis, and reduced glycogen synthesis, causing persistent hyperglycemia. When renal glucose threshold is exceeded, glucosuria occurs, leading to osmotic diuresis (polyuria, polydipsia) and compensatory polyphagia. Chronic hyperglycemia also causes non-enzymatic glycation of proteins, oxidative stress, and microvascular damage, contributing to complications such as neuropathy, nephropathy, and retinopathy. In dogs, T2DM is rare, but similar mechanisms can occur in secondary diabetes due to insulin resistance from hyperadrenocorticism or glucocorticoid therapy.

Intrinsic risk factors include genetic susceptibility (e.g., Burmese cats), age (older cats), and sex (neutered males). Obesity is the most significant modifiable risk factor, as it directly induces insulin resistance. Pancreatitis, whether acute or chronic, can damage beta-cells and predispose to diabetes. Endocrine disorders such as hyperadrenocorticism (Cushing's disease), acromegaly (excess growth hormone), and hyperthyroidism can cause insulin resistance. Exogenous factors include administration of diabetogenic drugs, particularly glucocorticoids (e.g., prednisolone, dexamethasone) and progestogens (e.g., megestrol acetate), which are used in cats for various conditions. A sedentary lifestyle and a diet high in carbohydrates and low in protein are also contributing factors. Stress, such as concurrent illness or hospitalization, can precipitate clinical diabetes in cats with underlying insulin resistance. In dogs, T2DM is rare, but risk factors for secondary diabetes include hyperadrenocorticism, diestrus in intact females, and chronic pancreatitis.

Clinical signs of T2DM typically develop gradually and may be subtle initially. The classic triad is polyuria, polydipsia, and polyphagia, often accompanied by weight loss despite a good appetite. In cats, signs may be insidious, with owners noticing increased urination (large clumps in litter box), increased water consumption, and a ravenous appetite. Weight loss occurs due to catabolism of fat and protein when glucose cannot be utilized. As the disease progresses, cats may develop a plantigrade stance (hindlimb weakness) due to diabetic neuropathy. In dogs, signs are similar but may progress more rapidly to diabetic ketoacidosis (DKA) if untreated. Other signs include lethargy, poor coat condition, and recurrent infections (e.g., urinary tract infections, skin infections). In advanced stages, cataracts may develop in dogs due to sorbitol accumulation in the lens, leading to sudden blindness. In cats, cataracts are rare. Physical examination may reveal obesity or emaciation, hepatomegaly (due to hepatic lipidosis or glycogen accumulation), and dehydration. In DKA, signs include vomiting, diarrhea, depression, and a fruity odor on the breath (ketones).

Differential diagnoses for polyuria and polydipsia (PU/PD) include: 1) Chronic kidney disease (CKD) - distinguished by azotemia, poorly concentrated urine (USG < 1.030 in cats, < 1.020 in dogs), and proteinuria. 2) Hyperthyroidism in cats - weight loss with polyphagia, elevated T4, and often a thyroid nodule. 3) Hyperadrenocorticism (Cushing's disease) - PU/PD, pot-bellied appearance, elevated cortisol on ACTH stimulation or low-dose dexamethasone suppression test. 4) Diabetes insipidus (central or nephrogenic) - urine specific gravity < 1.008, no glucosuria, response to desmopressin or water deprivation test. 5) Pyometra in intact females - vaginal discharge, systemic illness, leukocytosis, and imaging findings. 6) Acromegaly (hypersomatotropism) in cats - insulin resistance, large body size, broad facial features, elevated IGF-1. 7) Stress-induced hyperglycemia in cats - transient hyperglycemia without glucosuria or persistent hyperglycemia; resolution with stress reduction. 8) Exogenous glucocorticoid or progestogen administration - history of drug use. 9) Pancreatitis - abdominal pain, vomiting, elevated fPLI or cPLI, and imaging changes. 10) Hepatic lipidosis - often concurrent with diabetes, but can cause PU/PD and weight loss; diagnosis via liver biopsy or imaging. Definitive diagnosis of T2DM requires persistent hyperglycemia and glucosuria, along with consistent clinical signs.

The diagnostic algorithm for T2DM begins with a thorough history and physical examination, focusing on PU/PD, polyphagia, weight loss, and risk factors (obesity, age, breed). Initial laboratory tests include a complete blood count (CBC), serum biochemistry profile, and urinalysis. Key findings include hyperglycemia (fasting blood glucose > 180 mg/dL in cats, > 200 mg/dL in dogs), glucosuria, and possibly elevated liver enzymes (ALT, ALP) due to hepatic lipidosis. If hyperglycemia is borderline or stress-induced is suspected, a single measurement of fructosamine (a glycated protein reflecting average glucose over 2-3 weeks) can be helpful; fructosamine > 400 μmol/L in cats and > 350 μmol/L in dogs supports diabetes. If DKA is suspected, a blood gas analysis and serum ketone measurement (beta-hydroxybutyrate) should be performed. To differentiate T2DM from T1DM, measurement of serum insulin or C-peptide may be useful, but is not routinely performed; in cats, low insulin levels with hyperglycemia suggest beta-cell failure. Additional tests to rule out concurrent diseases include serum total T4 (hyperthyroidism), cortisol tests (hyperadrenocorticism), and abdominal ultrasound to assess the pancreas and adrenal glands. In cats, a diagnosis of T2DM is often made based on clinical signs, persistent hyperglycemia, and glucosuria, with response to insulin therapy and potential remission later. In dogs, T2DM is rare, and most cases are T1DM; however, if insulin resistance is suspected, further testing for hyperadrenocorticism or acromegaly is warranted.

Hematology: CBC is often unremarkable, but may show mild anemia of chronic disease or leukocytosis if infection is present. Serum Biochemistry: Hyperglycemia (fasting glucose > 180 mg/dL in cats, > 200 mg/dL in dogs) is the hallmark. Liver enzymes (ALT, ALP) may be mildly to moderately elevated due to hepatic lipidosis or glycogen accumulation. Cholesterol and triglycerides may be elevated due to dyslipidemia. Electrolyte abnormalities may include hypokalemia (due to osmotic diuresis) and hyponatremia (pseudohyponatremia if severe hyperglycemia). Blood gas analysis may reveal metabolic acidosis in DKA (pH < 7.3, bicarbonate < 15 mEq/L). Urinalysis: Glucosuria is present when blood glucose exceeds the renal threshold (approximately 180-220 mg/dL in cats and dogs). Urine specific gravity is often isosthenuric (1.008-1.012) due to osmotic diuresis, but may be concentrated if concurrent kidney disease. Ketonuria may be present in DKA. Proteinuria may indicate concurrent nephropathy. Specific biomarkers: Fructosamine is elevated (> 400 μmol/L in cats, > 350 μmol/L in dogs) and reflects average glucose over 2-3 weeks. Serum insulin or C-peptide may be low in T2DM, but is not routinely measured. In cats, a low serum insulin (< 10 μU/mL) with hyperglycemia suggests beta-cell exhaustion. In dogs, measurement of cPLI (canine pancreatic lipase immunoreactivity) may be indicated if pancreatitis is suspected. Serology/PCR: Not routinely used for T2DM, but may be performed to rule out infectious causes of pancreatitis (e.g., toxoplasmosis, feline coronavirus). Endocrinological assays: Total T4 to rule out hyperthyroidism, cortisol tests (ACTH stimulation or low-dose dexamethasone suppression) to rule out hyperadrenocorticism, and IGF-1 to rule out acromegaly in cats.

Radiography: Thoracic radiographs may show hepatomegaly (due to lipidosis) or evidence of concurrent heart disease. Abdominal radiographs may reveal hepatomegaly, but are not specific. Ultrasonography: Abdominal ultrasound is useful to assess the pancreas (chronic pancreatitis may show hypoechoic or hyperechoic parenchyma, irregular margins), liver (diffuse hyperechoic parenchyma suggestive of lipidosis), and adrenal glands (enlargement in hyperadrenocorticism). In cats, pancreatic ultrasound may be normal in T2DM. Doppler ultrasound can assess blood flow to the pancreas. Computed Tomography (CT): CT is rarely used for T2DM diagnosis but may be helpful to evaluate the pancreas for masses or calcification. Magnetic Resonance Imaging (MRI): MRI is not routinely used but may be indicated for suspected acromegaly (pituitary mass). Endoscopy: Endoscopic retrograde cholangiopancreatography (ERCP) is not commonly performed in veterinary medicine but could be used to evaluate pancreatic duct obstruction. Fluoroscopy: Not typically used. Echocardiography: May be indicated if concurrent cardiac disease is suspected, especially in cats with hyperthyroidism or hypertension.

Fine Needle Aspirate (FNA): FNA of the liver may be performed if hepatic lipidosis is suspected; cytology would show hepatocytes with vacuolated cytoplasm (lipid). FNA of the pancreas is rarely performed due to risk of pancreatitis. Fluid Analysis: If DKA is present, peritoneal fluid may be analyzed if pancreatitis is suspected; it may show a modified transudate or exudate with elevated protein and nucleated cell count. Histopathology: A definitive diagnosis of T2DM can be made by pancreatic biopsy, but this is rarely performed due to invasiveness. Histopathological findings include islet amyloid deposition (Congo red stain positive), reduced beta-cell mass, and fibrosis. In cats, amyloid deposits are characteristic. In dogs, T2DM is rare, but if present, similar changes may be seen. Special stains: Immunohistochemistry for insulin can demonstrate reduced beta-cell numbers. Histopathology of the liver may show hepatic lipidosis (vacuolated hepatocytes) or glycogen accumulation.

The treatment of T2DM in cats and dogs involves a multimodal approach: 1) Insulin therapy: In cats, intermediate-acting insulin such as glargine (Lantus) or protamine zinc insulin (PZI) is often used. Glargine is administered at an initial dose of 0.25-0.5 U/kg SC q12h, with dose adjustments based on serial blood glucose curves. PZI is given at 0.2-0.5 U/kg SC q12h. In dogs, NPH insulin (Humulin N) is commonly used at 0.25-0.5 U/kg SC q12h, but most dogs require higher doses (0.5-1.0 U/kg). Insulin therapy should be initiated after stabilizing the patient, especially if DKA is present. 2) Dietary management: For cats, a high-protein, low-carbohydrate diet (e.g., canned food) is recommended to reduce postprandial hyperglycemia and promote weight loss. For dogs, a high-fiber, complex-carbohydrate diet is often recommended to slow glucose absorption. Weight loss is crucial in obese cats; a goal of 0.5-1% body weight loss per week is appropriate. 3) Oral hypoglycemic agents: In cats, glipizide (2.5-5 mg PO q12h) may be used in early T2DM, but insulin is more effective. In dogs, oral agents are rarely effective. 4) Management of concurrent conditions: Treat underlying diseases such as hyperadrenocorticism, hyperthyroidism, or infections. 5) Emergency treatment of DKA: If DKA is present, aggressive fluid therapy with 0.9% NaCl, regular insulin (0.1 U/kg IV bolus, then 0.05-0.1 U/kg/hr CRI), potassium supplementation, and correction of acidosis are required. 6) Monitoring: Blood glucose curves should be performed every 1-2 weeks initially, then every 3-4 months. Fructosamine levels can be measured every 2-3 months. 7) In cats, remission is possible with early aggressive treatment; insulin dose should be tapered if blood glucose remains < 200 mg/dL.

The prognosis for T2DM in cats is generally good, especially if diagnosed early and treated aggressively. With appropriate insulin therapy and dietary management, many cats achieve remission, with reported remission rates of 30-80% in cats treated with glargine and a low-carbohydrate diet. Factors associated with a higher chance of remission include: initial blood glucose < 400 mg/dL, absence of ketoacidosis, and good owner compliance. However, if left untreated or poorly controlled, T2DM can lead to severe complications such as DKA, hepatic lipidosis, and neuropathy, which carry a guarded prognosis. In dogs, T2DM is rare, and most dogs require lifelong insulin therapy; the prognosis is good with proper management, but complications such as cataracts and recurrent infections can occur. The median survival time for diabetic dogs is approximately 2-3 years, but many live longer with good control. Negative prognostic indicators include: presence of concurrent diseases (e.g., pancreatitis, hyperadrenocorticism), poor response to insulin, and development of DKA.

Follow-up for T2DM involves regular monitoring of clinical signs, body weight, and blood glucose levels. Initially, re-check appointments should be scheduled every 1-2 weeks until stable. At each visit, a blood glucose curve (serial measurements every 2 hours over 12-24 hours) should be performed to assess insulin efficacy and duration. Fructosamine levels should be measured every 2-3 months to evaluate long-term glycemic control. Owners should be trained to monitor urine glucose and ketones at home, but urine glucose is not reliable for dose adjustments. Body weight should be monitored weekly during weight loss programs. If remission is achieved in cats, insulin dose should be gradually reduced based on blood glucose curves, and if blood glucose remains normal without insulin for 2-4 weeks, remission is confirmed. Long-term follow-up should include routine blood work (CBC, biochemistry, urinalysis) every 6-12 months to screen for complications such as kidney disease, urinary tract infections, and pancreatitis. Blood pressure should be checked periodically, as hypertension is common in diabetic cats.

Pearls: 1) In cats, stress hyperglycemia is common; always confirm with fructosamine or persistent hyperglycemia and glucosuria. 2) Glargine insulin is often preferred in cats due to its longer duration and higher remission rates. 3) A high-protein, low-carbohydrate diet is essential for managing feline T2DM. 4) Weight loss is the most effective way to improve insulin sensitivity in obese cats. 5) In dogs, most diabetes is T1DM; if a dog requires > 1.5 U/kg of insulin, suspect insulin resistance (e.g., hyperadrenocorticism, acromegaly). 6) Always rule out concurrent diseases such as hyperthyroidism, hyperadrenocorticism, and pancreatitis. Pitfalls: 1) Do not diagnose diabetes based on a single hyperglycemic reading in cats; stress can cause glucose > 300 mg/dL. 2) Avoid using oral hypoglycemics as sole therapy in cats with clinical signs; insulin is more effective. 3) Do not taper insulin too quickly in cats; remission should be confirmed with blood glucose curves. 4) Do not use short-acting insulin (regular) for maintenance therapy; it is only for DKA. 5) Do not ignore concurrent urinary tract infections, which are common in diabetic patients. 6) Do not forget to monitor for hypoglycemia, especially after insulin dose adjustments or if the cat starts eating poorly.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: 1) Insulin glargine (Lantus): For cats, initial dose 0.25-0.5 U/kg SC q12h, adjust by 0.5-1 U per dose every 5-7 days based on blood glucose curves. Maximum dose rarely exceeds 2 U/kg q12h. In dogs, not commonly used, but can be used at 0.5 U/kg q12h. 2) Protamine zinc insulin (PZI): For cats, initial dose 0.2-0.5 U/kg SC q12h, adjust similarly. 3) NPH insulin (Humulin N): For dogs, initial dose 0.25-0.5 U/kg SC q12h, but many dogs require 0.5-1.0 U/kg. Adjust by 10-25% every 5-7 days. 4) Regular insulin (Humulin R): For DKA, IV bolus 0.1 U/kg, then CRI at 0.05-0.1 U/kg/hr, titrated based on blood glucose. 5) Glipizide: For cats with early T2DM, 2.5-5 mg PO q12h, but not recommended as first-line. 6) Potassium chloride: For DKA, add to fluids at 20-40 mEq/L, depending on serum potassium. 7) Sodium bicarbonate: Only if pH < 7.1, use cautiously at 0.5-1 mEq/kg IV over 30-60 minutes. 8) Antibiotics: If concurrent infection, choose appropriate antibiotics (e.g., amoxicillin-clavulanate 12.5-25 mg/kg PO q12h for urinary tract infections). 9) Anti-emetics: If vomiting, maropitant 1 mg/kg SC q24h. 10) Nutritional support: If hepatic lipidosis, consider feeding tube (e.g., esophagostomy tube) with a high-protein diet. All doses should be adjusted based on renal/hepatic function and patient response.

Key studies and consensus guidelines: 1) The ACVIM Consensus Statement on the Diagnosis and Treatment of Diabetes Mellitus in Dogs and Cats (2018) provides evidence-based recommendations. It emphasizes the use of insulin as the cornerstone of therapy, with glargine and PZI preferred in cats. 2) A landmark study by Marshall et al. (2009) demonstrated that cats treated with glargine and a low-carbohydrate diet had a remission rate of 84% compared to 56% with PZI. 3) A study by Zini et al. (2016) showed that weight loss improves insulin sensitivity in obese cats. 4) The ISCAID guidelines (2019) recommend against the use of oral hypoglycemics as sole therapy in cats. 5) A meta-analysis by Gostelow et al. (2018) found that high-protein, low-carbohydrate diets are associated with higher remission rates. 6) In dogs, a study by Hess et al. (2000) found that the median survival time is 2 years, with good glycemic control improving outcomes. 7) The use of fructosamine for monitoring is supported by multiple studies, showing a good correlation with average glucose. 8) For DKA, a study by Hume et al. (2006) showed that low-dose insulin CRI is safe and effective. 9) The IRIS guidelines (2019) recommend monitoring for concurrent kidney disease in diabetic patients. 10) A recent study by Niessen et al. (2017) highlighted the importance of screening for acromegaly in cats with insulin resistance.